These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8825847)

  • 21. Long-term immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy.
    Rajabally YA
    Muscle Nerve; 2015 May; 51(5):657-61. PubMed ID: 25556954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dyshydrotic Eczema Secondary to Intravenous Immunoglobulin Infusion: A Report of 2 Cases.
    Garrido-Ríos AA; Martínez-Morán C; Borbujo J
    Actas Dermosifiliogr; 2016 Jun; 107(5):431-3. PubMed ID: 26768317
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of intravenous immunoglobulin in patients with active vasculitis associated with concomitant infection.
    Simoes J; Sciascia S; Camara I; Baldovino S; Karim Y; Roccatello D; Cuadrado MJ
    J Clin Rheumatol; 2015 Jan; 21(1):35-7. PubMed ID: 25539433
    [No Abstract]   [Full Text] [Related]  

  • 24. Human intravenous immunoglobulin-induced aseptic meningitis: a case report.
    Chaabane A; Hamzaoui A; Aouam K; Klai R; Fredj NB; Boughattas NA; Mahjoub S
    J Clin Pharmacol; 2012 Feb; 52(2):279-81. PubMed ID: 21257801
    [No Abstract]   [Full Text] [Related]  

  • 25. Immediate infusion-related adverse reactions to intravenous immunoglobulin in a prospective cohort of 1765 infusions.
    Bichuetti-Silva DC; Furlan FP; Nobre FA; Pereira CT; Gonçalves TR; Gouveia-Pereira M; Rota R; Tavares L; Mazzucchelli JT; Costa-Carvalho BT
    Int Immunopharmacol; 2014 Dec; 23(2):442-6. PubMed ID: 25257732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of intravenous immunoglobulin treatment.
    Caress JB; Kennedy BL; Eickman KD
    Expert Opin Drug Saf; 2010 Nov; 9(6):971-9. PubMed ID: 20408737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study.
    Debes A; Bauer M; Kremer S
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):1038-47. PubMed ID: 17636556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The new domestic immunoglobulin G gabriglobin in complex therapy of immunodeficiency states and infectious pathology].
    Pas'ko VG; Latysheva TV; Nikiforov VV; Mostovskaia EV; Denisov AK; Kondrashin IuI
    Voen Med Zh; 2006 Jul; 327(7):40-2. PubMed ID: 16977880
    [No Abstract]   [Full Text] [Related]  

  • 29. Intravenous immunoglobulin: production, uses and side effects.
    Cowden J; Parker SK
    Pediatr Infect Dis J; 2006 Jul; 25(7):641-2. PubMed ID: 16804436
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunoglobulin therapy: methods of delivery.
    Ballow M
    J Allergy Clin Immunol; 2008 Nov; 122(5):1038-9. PubMed ID: 18804269
    [No Abstract]   [Full Text] [Related]  

  • 31. Intravenous immunoglobulin in oncology nursing practice.
    Timmerman PR
    Oncol Nurs Forum; 1993; 20(1):69-75. PubMed ID: 8421651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pulmonary embolism associated with intravenous immunoglobulin therapy.
    Butler KS; Zeitlin DS
    Ann Pharmacother; 2003 Oct; 37(10):1530. PubMed ID: 14519037
    [No Abstract]   [Full Text] [Related]  

  • 33. [Intravenous immunoglobulin infusion treatment for pneumoconiosis complicated with severe asthma in coal miners ].
    Zhao JN; Wang P
    Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2003 Jun; 21(3):234-5. PubMed ID: 14761506
    [No Abstract]   [Full Text] [Related]  

  • 34. Aseptic meningitis as a complication of intravenous immunoglobulin therapy for myasthenia gravis.
    Ellis RJ; Swendson MR; Bajorek J
    Muscle Nerve; 1994 Jun; 17(6):683-4. PubMed ID: 8196714
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy.
    Donofrio PD; Bril V; Dalakas MC; Deng C; Hanna K; Hartung HP; Hughes R; Latov N; Merkies I; van Doorn P;
    Arch Neurol; 2010 Sep; 67(9):1082-8. PubMed ID: 20837852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nursing guidelines for administration of immunoglobulin replacement therapy.
    Younger ME; Aro L; Blouin W; Duff C; Epland KB; Murphy E; Sedlak D;
    J Infus Nurs; 2013; 36(1):58-68. PubMed ID: 23271153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia.
    Björkander J; Nikoskelainen J; Leibl H; Lanbeck P; Wallvik J; Lumio JT; Braconier JH; Pavlova BG; Birthistle K; Engl W; Walter S; Ehrlich HJ
    Vox Sang; 2006 May; 90(4):286-93. PubMed ID: 16635071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of chronic inflammatory demyelinating polyneuropathy with high-dose intermittent intravenous methylprednisolone.
    Lopate G; Pestronk A; Al-Lozi M
    Arch Neurol; 2005 Feb; 62(2):249-54. PubMed ID: 15710853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expert opinion regarding clinical and other outcome considerations in the formulary review of immune globulin.
    Sorensen R
    J Manag Care Pharm; 2007 Apr; 13(3):278-83. PubMed ID: 17407395
    [No Abstract]   [Full Text] [Related]  

  • 40. Current perspectives on the use of intravenous immunoglobulin.
    Dickler HB; Gelfand EW
    Adv Intern Med; 1996; 41():641-80. PubMed ID: 8903601
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.